SCHEMBL16247707

SCHEMBL16247707

COC1OC(OC=O)[C@@H](O)C(OC2OC(OCO)[C@@H](OC)C(O)[C@@H]2O)[C@@H]1NC(C)=O

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 7/20 0.39
▸ LGALS8 O00214 1/20 0.39
▸ LGALS4 P56470 1/20 0.39
▸ LGALS7; LGALS7B P47929 2/20 0.37
▸ LGALS1 P09382 1/20 0.37
▸ LGALS9 O00182 2/20 0.36
▸ CD69 Q07108 1/20 0.35
▸ MAPK1 P28482 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ BDNF P23560 2/20 0.33
▸ PTN P21246 1/20 0.33
▸ MDK P21741 1/20 0.33
▸ CHIA Q9BZP6 1/20 0.32
▸ MMP9 P14780 1/20 0.31
▸ MMP12 P39900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13815458 0.87 LGALS3 (0.34) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL14883305 0.85 CD69 (0.34) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL17212844 0.83 LGALS3 (0.46) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL15274901 0.78 LGALS3 (0.45) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL16659352 0.78 LGALS3 (0.45) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL18589697 0.78 LGALS3 (0.45) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL17849187 0.76 LGALS3 (0.55) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL20175842 0.76 LGALS3 (0.52) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL17849186 0.73 LGALS3 (0.54) LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1
SCHEMBL18053147 0.73 M6PR (0.34) LGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9511088-B2 Stabalized glycosaminoglycan preparations and related methods S.K. PHARMACEUTICALS, INC. (US) 2016-12-06 — — US disclosed
US-20140343013-A1 Stabalized Glycosaminoglycan Preparations and Related Methods S.K. PHARMACEUTICALS (US) 2014-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343013-A1 Stabalized Glycosaminoglycan Preparations and Related Methods CD44, PLOD3, EGLN3 LGALS3 443/4885LGALS8 1307/4885LGALS4 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback